Skip to Main content Skip to Navigation
Journal articles

Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer’s Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins

Abstract : Background/objective: The aim of this study was to assess, in routine, the rates with which an amyloid deposition was documented by 18F-florbetaben PET in patients with suspected Alzheimer's disease (AD) but with isolated increases in cerebrospinal fluid (CSF) tau-protein concentrations, and the subsequent impact of these PET results on medical management. Methods: This prospective study included 34 patients with mild neurocognitive disorders (MND) and suspected AD (73±9 years, 16 women) and with abnormal CSF concentrations in total-tau (T-tau) and/or phosphorylated-tau (P-tau) proteins but normal Aβ42 concentration and Aβ42/Aβ40 ratio. These patients were referred to 8F-florbetaben PET from which the PET-related changes in the confidence for AD diagnosis (low, intermediate, or high) and treatments were reported. Results: The PET examinations were positive for amyloid deposition (brain amyloid plaque load, BAPL score >1) in none of the 9 patients with an increase in only T-tau proteins and in 8 among the 25 (32%) with an increase in P-tau proteins (one BAPL score of 2 and seven BAPL scores of 3). Knowledge of the PET results was associated with subsequent changes in diagnostic confidence in 44% of patients (15/34) and in the intention-to-treat with a cholinesterase inhibitor drug in 18% (6/34). Conclusion: In patients with suspected AD and isolated increase in CSF tau protein concentrations, an amyloid deposition is documented by 18F-florbetaben PET in as much as one third of cases when the concentration of P-tau is abnormal, and PET results are associated with significant further changes in medical management.
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03266997
Contributor : Juliette Birker <>
Submitted on : Tuesday, June 22, 2021 - 11:36:20 AM
Last modification on : Thursday, August 26, 2021 - 9:38:01 AM

Identifiers

Collections

Citation

Chloé Manca, Lucie Hopes, Anna Kearney-Schwartz, Véronique Roch, Gilles Karcher, et al.. Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer’s Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins. Journal of Alzheimer's Disease, IOS Press, 2019, 68 (3), pp.1061-1069. ⟨10.3233/JAD-181146⟩. ⟨hal-03266997⟩

Share

Metrics

Record views

24